347 related articles for article (PubMed ID: 29238070)
1. The interplay between mutant p53 and the mevalonate pathway.
Parrales A; Thoenen E; Iwakuma T
Cell Death Differ; 2018 Mar; 25(3):460-470. PubMed ID: 29238070
[TBL] [Abstract][Full Text] [Related]
2. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.
Parrales A; Ranjan A; Iyer SV; Padhye S; Weir SJ; Roy A; Iwakuma T
Nat Cell Biol; 2016 Nov; 18(11):1233-1243. PubMed ID: 27775703
[TBL] [Abstract][Full Text] [Related]
3. Key roles of Rho GTPases, YAP, and Mutant P53 in anti-neoplastic effects of statins.
Ji L; Liu C; Yuan Y; Gao H; Tang ZX; Yang Z; Liu ZT; Jiang GH
Fundam Clin Pharmacol; 2020 Feb; 34(1):4-10. PubMed ID: 31241783
[TBL] [Abstract][Full Text] [Related]
4. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1.
Tong X; Xu D; Mishra RK; Jones RD; Sun L; Schiltz GE; Liao J; Yang GY
J Biol Chem; 2021; 296():100098. PubMed ID: 33208462
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations.
Meng X; Gao JZ; Gomendoza SMT; Li JW; Yang S
Front Med (Lausanne); 2021; 8():737951. PubMed ID: 34671620
[TBL] [Abstract][Full Text] [Related]
6. The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer.
Liu J; Zhang C; Xu D; Zhang T; Chang CY; Wang J; Liu J; Zhang L; Haffty BG; Zong WX; Hu W; Feng Z
J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36749630
[TBL] [Abstract][Full Text] [Related]
7. Gain-of-function mutant p53 in cancer progression and therapy.
Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
[TBL] [Abstract][Full Text] [Related]
8. DNAJA1 promotes cancer metastasis through interaction with mutant p53.
Kaida A; Yamamoto S; Parrales A; Young ED; Ranjan A; Alalem MA; Morita KI; Oikawa Y; Harada H; Ikeda T; Thomas SM; Diaz FJ; Iwakuma T
Oncogene; 2021 Aug; 40(31):5013-5025. PubMed ID: 34183772
[TBL] [Abstract][Full Text] [Related]
9. Mevalonate Pathway Provides Ubiquinone to Maintain Pyrimidine Synthesis and Survival in p53-Deficient Cancer Cells Exposed to Metabolic Stress.
Kaymak I; Maier CR; Schmitz W; Campbell AD; Dankworth B; Ade CP; Walz S; Paauwe M; Kalogirou C; Marouf H; Rosenfeldt MT; Gay DM; McGregor GH; Sansom OJ; Schulze A
Cancer Res; 2020 Jan; 80(2):189-203. PubMed ID: 31744820
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches.
Alvarado-Ortiz E; de la Cruz-López KG; Becerril-Rico J; Sarabia-Sánchez MA; Ortiz-Sánchez E; García-Carrancá A
Front Cell Dev Biol; 2020; 8():607670. PubMed ID: 33644030
[TBL] [Abstract][Full Text] [Related]
11. PBA Preferentially Impairs Cell Survival of Glioblastomas Carrying mutp53 by Reducing Its Expression Level, Stabilizing wtp53, Downregulating the Mevalonate Kinase and Dysregulating UPR.
Romeo MA; Gilardini Montani MS; Benedetti R; Garufi A; D'Orazi G; Cirone M
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32290231
[TBL] [Abstract][Full Text] [Related]
12. Metabolic control of YAP and TAZ by the mevalonate pathway.
Sorrentino G; Ruggeri N; Specchia V; Cordenonsi M; Mano M; Dupont S; Manfrin A; Ingallina E; Sommaggio R; Piazza S; Rosato A; Piccolo S; Del Sal G
Nat Cell Biol; 2014 Apr; 16(4):357-66. PubMed ID: 24658687
[TBL] [Abstract][Full Text] [Related]
13. Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53.
Zhao Y; Zhang C; Yue X; Li X; Liu J; Yu H; Belyi VA; Yang Q; Feng Z; Hu W
Cell Death Differ; 2015 Nov; 22(11):1824-36. PubMed ID: 25857266
[TBL] [Abstract][Full Text] [Related]
14. Regulators of Oncogenic Mutant TP53 Gain of Function.
Yamamoto S; Iwakuma T
Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30577483
[TBL] [Abstract][Full Text] [Related]
15. BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function.
Yue X; Zhao Y; Liu J; Zhang C; Yu H; Wang J; Zheng T; Liu L; Li J; Feng Z; Hu W
Elife; 2015 Aug; 4():. PubMed ID: 26271008
[TBL] [Abstract][Full Text] [Related]
16. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
[TBL] [Abstract][Full Text] [Related]
17. DNAJA1- and conformational mutant p53-dependent inhibition of cancer cell migration by a novel compound identified through a virtual screen.
Nishikawa S; Kaida A; Parrales A; Ranjan A; Alalem M; Ren H; Schoenen FJ; Johnson DK; Iwakuma T
Cell Death Discov; 2022 Oct; 8(1):437. PubMed ID: 36316326
[TBL] [Abstract][Full Text] [Related]
18. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 Depletion by Novel Inhibitors for HSP40/J-Domain Proteins Derived from the Natural Compound Plumbagin.
Alalem M; Bhosale M; Ranjan A; Yamamoto S; Kaida A; Nishikawa S; Parrales A; Farooki S; Anant S; Padhye S; Iwakuma T
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077724
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
